Enjaymo (Sutimlimab-jome) for AIHA

Overview
Enjaymo is a prescription drug approved by the U.S. Food and Drug Administration (FDA) in 2022 to treat cold agglutinin disease (CAD), a type of autoimmune hemolytic anemia (AIHA). Enjaymo is also known by its drug name, sutimlimab-jome.

Enjaymo is a monoclonal antibody that interferes with the breakdown of red blood cells (hemolysis). Enjaymo is believed to decrease the need for red blood cell transfusion in people with CAD.

How do I take it?
Enjaymo is administered as an intravenous injection.

Side effects
The FDA-approved label for Enjaymo lists common side effects including respiratory tract infections, viral infections, diarrhea, indigestion, cough, muscle weakness, joint pain, and swelling of the lower legs and feet.

Rare but serious side effects listed for Enjaymo include serious infection, infusion-related reactions, and development of autoimmune disease.

For more details about this treatment, visit:

Enjaymo — Sanofi
https://www.enjaymo.com/treating-with-ENJAYMO.aspx

Enjaymo: First Drug To Treat Cold Agglutinin Disease — BioPharma Media
https://biopharma.media/enjaymo-first-drug-to-t...